JP2022547324A - 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法 - Google Patents

網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法 Download PDF

Info

Publication number
JP2022547324A
JP2022547324A JP2022516058A JP2022516058A JP2022547324A JP 2022547324 A JP2022547324 A JP 2022547324A JP 2022516058 A JP2022516058 A JP 2022516058A JP 2022516058 A JP2022516058 A JP 2022516058A JP 2022547324 A JP2022547324 A JP 2022547324A
Authority
JP
Japan
Prior art keywords
retinal
hemichannel
alkyl
subject
choroidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547324A5 (enExample
Inventor
コリン リチャード グリーン，
ナルシル マト ノル，
モニカ リリアーナ アコスタ エチェバーン，
ブラッドフォード ジェイムズ ダフト，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of JP2022547324A publication Critical patent/JP2022547324A/ja
Publication of JP2022547324A5 publication Critical patent/JP2022547324A5/ja
Priority to JP2025156573A priority Critical patent/JP2025181930A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022516058A 2019-09-13 2020-09-11 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法 Pending JP2022547324A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025156573A JP2025181930A (ja) 2019-09-13 2025-09-19 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900379P 2019-09-13 2019-09-13
US62/900,379 2019-09-13
US201962903504P 2019-09-20 2019-09-20
US62/903,504 2019-09-20
PCT/US2020/050579 WO2021051015A1 (en) 2019-09-13 2020-09-11 Compositions and methods for rescuing retinal and choroidal structure and function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025156573A Division JP2025181930A (ja) 2019-09-13 2025-09-19 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法

Publications (2)

Publication Number Publication Date
JP2022547324A true JP2022547324A (ja) 2022-11-11
JP2022547324A5 JP2022547324A5 (enExample) 2023-09-20

Family

ID=74866757

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516058A Pending JP2022547324A (ja) 2019-09-13 2020-09-11 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法
JP2025156573A Pending JP2025181930A (ja) 2019-09-13 2025-09-19 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025156573A Pending JP2025181930A (ja) 2019-09-13 2025-09-19 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法

Country Status (6)

Country Link
US (1) US20220401408A1 (enExample)
EP (1) EP4027992A4 (enExample)
JP (2) JP2022547324A (enExample)
CN (2) CN114727981B (enExample)
CA (1) CA3154499A1 (enExample)
WO (1) WO2021051015A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025219925A1 (en) * 2024-04-19 2025-10-23 Auckland Uniservices Limited Compounds for treatment and prevention of diseases, disorders and conditions
WO2025219923A1 (en) * 2024-04-19 2025-10-23 Auckland Uniservices Limited Modulators for treatment and prevention of diseases, disorders and conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526687A (ja) * 2014-08-22 2017-09-14 オークランド ユニサービシーズ リミティド チャネル調節剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281524A1 (en) * 2008-06-05 2013-10-24 Peter Blower Novel treatments
EP2506847A1 (en) * 2009-12-03 2012-10-10 Proximagen Limited Treatment of infectious diseases
JP6898848B2 (ja) * 2014-09-19 2021-07-07 メモリアル スローン ケタリング キャンサー センター 脳転移を治療するための方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526687A (ja) * 2014-08-22 2017-09-14 オークランド ユニサービシーズ リミティド チャネル調節剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREEN, COLIN ET AL.: "TARGETING THE INFLAMMASOMEPATHWAY IN RETINAL DISEASE - AN ORALTREATMENT FOR AMD", CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, vol. Volume 45, S1208, JPN6024039031, 2017, pages 32 - 33, ISSN: 0005424617 *
GREEN, COLIN, R. ET AL.: "Connexin hemichannel block shuts down inflammation in an animal model of chronic diabetic retinopath", ARVO ANNUAL MEETING ABSTRACT, vol. Volume 60, Issue 9, JPN6024039032, July 2019 (2019-07-01), ISSN: 0005424616 *

Also Published As

Publication number Publication date
JP2025181930A (ja) 2025-12-11
CA3154499A1 (en) 2021-03-18
EP4027992A1 (en) 2022-07-20
US20220401408A1 (en) 2022-12-22
CN114727981A (zh) 2022-07-08
CN114727981B (zh) 2026-03-31
WO2021051015A1 (en) 2021-03-18
EP4027992A4 (en) 2023-11-29
CN121846082A (zh) 2026-04-14

Similar Documents

Publication Publication Date Title
Huang et al. Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia
Lambert et al. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
Adams et al. Glaucoma-Next Generation Therapeutics: Impossible to Possible: Adams et al.
HRP20040406A2 (en) Methods for treating ocular neovascular diseases
JP2025181930A (ja) 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法
Lambert et al. Nanosponge-mediated drug delivery lowers intraocular pressure
US20210315890A1 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
CN111683682A (zh) 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
WO2011097577A2 (en) Compositions and methods for treating or preventing retinal degeneration
US11707445B2 (en) Composition for blocking angiogenesis
US20240148709A1 (en) Methods of treating eye pain and eye disorders
MX2013011684A (es) Preparaciones oftalmicas basadas en el polipeptido activador de la adenilato ciclasa de la pituitaria que restauran la funcion visual normal en glaucoma temprano.
HK40080560A (en) Compositions and methods for rescuing retinal and choroidal structure and function
TWI848332B (zh) 抗血管生成之自組裝奈米粒子及其用途
Le The Neuroprotective Effects of SA-10 PLGA Nanoparticles in a Mouse Model of Retinal Ischemia/Reperfusion Injury
Jain Neuroprotection of the Optic Nerve and the Retina
WO2017202227A1 (zh) Z-亚丁基苯酞于活化自体免疫系统的应用
WO2025049588A1 (en) Novel treatments for optic neuropathies and glaucoma
WO2024220474A1 (en) Methods of treating age-related macular degeneration targeting igfbpl-1
JP2024510943A (ja) 上皮間葉転換をモジュレートするための組成物および方法
KR20180089819A (ko) 인돌-3-카비놀 또는 이의 약제학적으로 허용되는 염을 포함하는 당뇨 망막병증의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A603 Late request for extension of time limit during examination

Free format text: JAPANESE INTERMEDIATE CODE: A603

Effective date: 20250228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919